Ramjee M K, Henderson I M, McLoughlin S B, Padova A
Peptide Therapeutics, Cambridge, UK.
Thromb Res. 2000 Jun 15;98(6):559-69. doi: 10.1016/s0049-3848(00)00206-1.
Nafamostat mesilate (FUT-175), a synthetic serine protease inhibitor, is active against a number of the serine proteases involved in coagulation. This has been proposed as the basis of its anticoagulant activity. We investigated the reaction of Nafamostat with bovine pancreatic trypsin as a model system. It was shown to act as a time-dependent competitive inhibitor, and the inhibition constants for the binding of Nafamostat to trypsin (i.e., Ki) and the overall inhibition constants (i.e., Ki*) were calculated to be 11.5 microM and 0.4+/-0.14 nM, respectively. The second-order rate constant for the reaction was 4.5+/-0.19x10(5) M(-1)s(-1), and the product released following the acylation step, 6-amidino2-naphthol, showed mixed-type inhibition. The competitive (Kic) and uncompetitive (Kiu) inhibition constants were 14.7 microM and 19.5 microM, respectively. Formation of the acyl-enzyme intermediate was dissected into at least two steps, with rates of 0.9 s(-1) and 195 s(-1). The deacylation step was relatively much slower (3.2+/-0.19x10(-5) s(-1), enabling the mass spectroscopic analysis of the acyl-enzyme intermediate, which confirmed the covalent attachment of 4-guanidinobenzoic acid to trypsin. The product of the deacylation step, 4-guanidinobenzoic acid, showed no inhibition up to a concentration of 200 microM. These data strongly suggest that while Nafamostat is a potent inhibitor of trypsin, it is actually an extremely poor substrate, and that apparent inhibition is due to the competitive formation of a very stable acyl-enzyme intermediate, analogous to some other active site titrants.
甲磺酸萘莫司他(FUT - 175)是一种合成的丝氨酸蛋白酶抑制剂,对多种参与凝血的丝氨酸蛋白酶具有活性。这被认为是其抗凝活性的基础。我们以牛胰蛋白酶作为模型系统研究了甲磺酸萘莫司他的反应。结果表明它作为一种时间依赖性竞争性抑制剂,甲磺酸萘莫司他与胰蛋白酶结合的抑制常数(即Ki)和总抑制常数(即Ki*)经计算分别为11.5微摩尔/升和0.4±0.14纳摩尔/升。该反应的二级速率常数为4.5±0.19×10⁵摩尔⁻¹秒⁻¹,酰化步骤后释放的产物6 - 脒基 - 2 - 萘酚表现出混合型抑制。竞争性抑制常数(Kic)和非竞争性抑制常数(Kiu)分别为14.7微摩尔/升和19.5微摩尔/升。酰基酶中间体的形成至少分为两步,速率分别为0.9秒⁻¹和195秒⁻¹。脱酰基步骤相对慢得多(3.2±0.19×10⁻⁵秒⁻¹),这使得能够对酰基酶中间体进行质谱分析,证实了4 - 胍基苯甲酸与胰蛋白酶的共价连接。脱酰基步骤的产物4 - 胍基苯甲酸在浓度高达200微摩尔/升时未表现出抑制作用。这些数据有力地表明,虽然甲磺酸萘莫司他是胰蛋白酶的强效抑制剂,但实际上它是一种极差的底物,表观抑制是由于形成了非常稳定的酰基酶中间体的竞争性反应,这与其他一些活性位点滴定剂类似。